Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus gut microbiota modulation for recurrent or metastatic cervical cancer after prior systemic therapy
ChiCTR2600131529Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate. Started Feb 2025; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600131529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131529.